228 related articles for article (PubMed ID: 18509643)
1. Toxicity and toxicokinetics of the cyclin-dependent kinase inhibitor AG-024322 in cynomolgus monkeys following intravenous infusion.
Brown AP; Courtney CL; Criswell KA; Holliman CL; Evering W; Jessen BA
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1091-101. PubMed ID: 18509643
[TBL] [Abstract][Full Text] [Related]
2. Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance.
Glaze ER; Lambert AL; Smith AC; Page JG; Johnson WD; McCormick DL; Brown AP; Levine BS; Covey JM; Egorin MJ; Eiseman JL; Holleran JL; Sausville EA; Tomaszewski JE
Cancer Chemother Pharmacol; 2005 Dec; 56(6):637-47. PubMed ID: 15986212
[TBL] [Abstract][Full Text] [Related]
3. Toxicity of a quinocarmycin analog, DX-52-1, in rats and dogs in relation to clinical outcome.
Mirsalis JC; Schindler-Horvat J; Hill JR; Green CE; Mitoma C; Tomaszewski JE; Tyson CA; Donohue SJ
Cancer Chemother Pharmacol; 2003 Mar; 51(3):193-201. PubMed ID: 12655436
[TBL] [Abstract][Full Text] [Related]
4. Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys.
Working PK; Newman MS; Sullivan T; Brunner M; Podell M; Sahenk Z; Turner N
Toxicol Sci; 1998 Nov; 46(1):155-65. PubMed ID: 9928679
[TBL] [Abstract][Full Text] [Related]
5. Preclinical toxicity studies of kahalalide F, a new anticancer agent: single and multiple dosing regimens in the rat.
Brown AP; Morrissey RL; Faircloth GT; Levine BS
Cancer Chemother Pharmacol; 2002 Oct; 50(4):333-40. PubMed ID: 12357309
[TBL] [Abstract][Full Text] [Related]
6. General 4-week toxicity study with EMS in the rat.
Pfister T; Eichinger-Chapelon A
Toxicol Lett; 2009 Nov; 190(3):271-85. PubMed ID: 19442710
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys.
Monteith DK; Geary RS; Leeds JM; Johnston J; Monia BP; Levin AA
Toxicol Sci; 1998 Dec; 46(2):365-75. PubMed ID: 10048140
[TBL] [Abstract][Full Text] [Related]
8. Retinal and peripheral nerve toxicity induced by the administration of a pan-cyclin dependent kinase (cdk) inhibitor in mice.
Illanes O; Anderson S; Niesman M; Zwick L; Jessen BA
Toxicol Pathol; 2006; 34(3):243-8. PubMed ID: 16698721
[TBL] [Abstract][Full Text] [Related]
9. Drug safety evaluation through biomarker analysis--a toxicity study in the cynomolgus monkey using an antibody-cytotoxic conjugate against ovarian cancer.
Hsieh FY; Tengstrand E; Lee JW; Li LY; Silverman L; Riordan B; Miwa G; Milton M; Alden C; Lee F
Toxicol Appl Pharmacol; 2007 Oct; 224(1):12-8. PubMed ID: 17681578
[TBL] [Abstract][Full Text] [Related]
10. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
[TBL] [Abstract][Full Text] [Related]
11. Toxicology and pharmacokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor, in cynomolgus monkeys.
Hotchkiss CE; Hall PD; Cline JM; Willingham MC; Kreitman RJ; Gardin J; Latimer A; Ramage J; Feely T; DeLatte S; Tagge EP; Frankel AE
Toxicol Appl Pharmacol; 1999 Jul; 158(2):152-60. PubMed ID: 10406930
[TBL] [Abstract][Full Text] [Related]
12. Peripheral white blood cell toxicity induced by broad spectrum cyclin-dependent kinase inhibitors.
Jessen BA; Lee L; Koudriakova T; Haines M; Lundgren K; Price S; Nonomiya J; Lewis C; Stevens GJ
J Appl Toxicol; 2007; 27(2):133-42. PubMed ID: 17211896
[TBL] [Abstract][Full Text] [Related]
13. Risk and safety assessment of exogenous human brain natriuretic peptide in cynomolgus monkeys (Macaca fascicularis)--a subchronic study.
Mao Y; Zhao Y; Zhang X; Zheng J; Lu G; Yuan B
Regul Toxicol Pharmacol; 2010 Mar; 56(2):148-55. PubMed ID: 19766684
[TBL] [Abstract][Full Text] [Related]
14. Exposure-based safety evaluation of recombinant human macrophage colony-stimulating factor (M-CSF) in cynomolgus monkeys.
McCabe RD; Childs AL; Reynolds D; Johnson DE
Toxicol Sci; 1998 May; 43(1):61-7. PubMed ID: 9629620
[TBL] [Abstract][Full Text] [Related]
15. Subacute toxicity and toxicokinetics of CJ-10882, a type IV phosphodiesterase inhibitor, after 4-week repeated oral administration in dogs.
Han J; Shin HC; Kim JC; Kim B
Food Chem Toxicol; 2004 Mar; 42(3):373-80. PubMed ID: 14871579
[TBL] [Abstract][Full Text] [Related]
16. Comparative preclinical toxicology and pharmacology of isophosphoramide mustard, the active metabolite of ifosfamide.
Germann N; Urien S; Rodgers AH; Ratterree M; Struck RF; Waud WR; Serota DG; Bastian G; Jursic BS; Morgan LR
Cancer Chemother Pharmacol; 2005 Feb; 55(2):143-51. PubMed ID: 15592722
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.
Dean E; Jodrell D; Connolly K; Danson S; Jolivet J; Durkin J; Morris S; Jowle D; Ward T; Cummings J; Dickinson G; Aarons L; Lacasse E; Robson L; Dive C; Ranson M
J Clin Oncol; 2009 Apr; 27(10):1660-6. PubMed ID: 19237630
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
19. Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors.
Patyna S; Arrigoni C; Terron A; Kim TW; Heward JK; Vonderfecht SL; Denlinger R; Turnquist SE; Evering W
Toxicol Pathol; 2008 Dec; 36(7):905-16. PubMed ID: 18981453
[TBL] [Abstract][Full Text] [Related]
20. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
